Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 17:28:1610037.
doi: 10.3389/pore.2022.1610037. eCollection 2022.

Circular RNAs as Diagnostic and Prognostic Indicators of Colorectal Cancer: A Pooled Analysis of Individual Studies

Affiliations

Circular RNAs as Diagnostic and Prognostic Indicators of Colorectal Cancer: A Pooled Analysis of Individual Studies

Cong Long et al. Pathol Oncol Res. .

Abstract

Background: Circular RNAs (circRNAs) have proven as a special subset of endogenous RNAs that are implicated in the tumorigenesis of various cancers. This study sought to evaluate the role of circRNAs in the diagnosis and prognosis of colorectal cancer (CRC). Methods: The online databases were searched for collecting relevant studies on circRNAs as diagnostic and prognostic biomarkers of CRC. Two researchers independently screened literature, extracted data, and evaluated the bias and risks of included studies. The diagnostic and prognostic indicators were merged and analyzed using STATA 12.0 software, and sources of heterogeneity were traced by the sensitivity analysis and the meta-regression test. Results: A total of 29 articles representing 2639 CRC patients were included. The pooled sensitivity, specificity, and area under the curve (AUC) of circRNAs in differentiating CRC from non-tumor control were 0.75 (95% CI: 0.69-0.80) and 0.74 (95% CI: 0.69-0.78) and 0.81, respectively. The survival analysis showed that up-regulations of up-regulated circRNAs were significantly related to dismal survival in CRC patients (HR = 2.38, p < 0.001). A stratified analysis showed that the comprehensive diagnostic value of up-regualted circRNAs in CRC was higher than that of down-regualted circRNAs (AUC: 0.83 vs. 0.77; Z test, p < 0.05). The efficacy of tissue-derived circRNAs in the diagnosis of CRC was equal to that of plasma/serum-derived ones (AUC: 0.81 vs. 0.82; Z test, p > 0.05). Conclusion: Abnormally expressed circRNAs as auxiliary biomarkers present underlying value in the diagnosis and prognosis prediction of CRC.

Keywords: circular RNA; colorectal cancer; diagnosis; pooled analysis; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The flow chart of literature inclusion and exclusion process according to the PRISMA statement.
FIGURE 2
FIGURE 2
Forest plots of pooled (A) sensitivity, (B) specificity, (C) DOR, and (D) AUC for the diagnostic effect of circRNAs in CRC.
FIGURE 3
FIGURE 3
Forest plots of the prognostic effect of (A) up-regulated, (B) un-adjusted down-regulated circRNAs and (C) adjusted down-regulated circRNAs on survival in CRC patients.
FIGURE 4
FIGURE 4
The influence analysis of the homogeneity among the included studies. (A) the overall diagnostic efficacy of the studies. (B) the diagnostic efficacy of plasma/serum-based circRNA testing. (C) up-regulated and (D) down-regulated circRNAs in predicting the OS in CRC patients.
FIGURE 5
FIGURE 5
Appraising the publication bias among the included studies. (A) the overall diagnostic effect assessed by the Deek’s funnel plot. Begg’s test for the effects of (B) down-regulated and (C) up-regulated circRNAs in predicting the OS in CRC patients. (D) funnel plot of the trim-and-fill method shows no significant impacts on the combined effect of up-regulated circRNAs in CRC.

Similar articles

Cited by

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA A Cancer J Clin (2021) 71(1):7–33. PMID: 33433946. 10.3322/caac.21654 - DOI - PubMed
    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer Statistics in China, 2015. CA: a Cancer J clinicians (2016) 66(2):115–32. PMID: 26808342. 10.3322/caac.21338 - DOI - PubMed
    1. Simon K. Colorectal Cancer Development and Advances in Screening. Clin Interv Aging (2016) 11:967–76. PMID: 27486317. 10.2147/CIA.S109285 - DOI - PMC - PubMed
    1. Díaz-Tasende J. Colorectal Cancer Screening and Survival. Rev Esp Enferm Dig (2018) 110(11):681–3. PMID: 30284905. 10.17235/reed.2018.5870/2018 - DOI - PubMed
    1. Maida M, Macaluso FS, Ianiro G, Mangiola F, Sinagra E, Hold G, et al. Screening of Colorectal Cancer: Present and Future. Expert Rev Anticancer Ther (2017) 17(12):1131–46. PMID: 29022408. 10.1080/14737140.2017.1392243 - DOI - PubMed